Table 3 Treatment-emergent adverse events reported by at least 20% of patients and grade 3 and higher incidence of these events
From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Event term | Treatment-emergent adverse events (any grade) | Any grade 3 events | Any grade 4 events | Any grade 5 events |
|---|---|---|---|---|
Any event, n (%) | 28 (97) | 8 (28) | 3 (10) | 3 (10) |
Peripheral sensory neuropathy | 17 (59) | 2 (7) | 0 | 0 |
Fatigue | 12 (41) | 3 (10) | 1 (3) | 0 |
Nausea | 12 (41) | 1 (3) | 0 | 0 |
Diarrhea | 11 (38) | 0 | 0 | 0 |
Arthralgia | 8 (28) | 2 (7) | 0 | 0 |
Headache | 8 (28) | 0 | 0 | 0 |
Peripheral motor neuropathy | 8 (28) | 2 (7) | 0 | 0 |
Pyrexia | 8 (28) | 0 | 0 | 0 |
Anemia | 7 (24) | 5 (17) | 0 | 0 |
Dyspnea | 7 (24) | 1 (3) | 1 (3) | 0 |
Back pain | 6 (21) | 1 (3) | 0 | 0 |